Format

Send to

Choose Destination
See comment in PubMed Commons below
Acta Clin Belg. 2012 Nov-Dec;67(6):399-402.

Immunotherapy in leukaemia.

Author information

1
Antwerp University Hospital, Division of Haematology, Edgem, Belgium. Ann.Van.De.Velde@uza.ba

Abstract

Therapeutic cancer vaccination, e.g. by using tumour antigen-presenting dendritic cells (DCs) that 'educate' the immune system to recognise and attack tumour cells, represents a new concept of treatment in oncology. DCbased immunotherapy elicits both innate (NK) and adaptive (T cells) cellular responses correlated with clinical benefit. WT1 mRNA-transfected DCs emerge as a feasible and effective strategy to control residual disease in acute myeloid leukaemia (AML), in particular as a post-remission treatment to prevent full relapse. This innovative approach takes advantage of the intrinsic potential of the immune system to eradicate malignant disease.

PMID:
23340144
DOI:
10.2143/ACB.67.6.2062703
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center